<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-O596QE59/d8ae40f1-4052-465b-a0fa-64a110f7ad70/PDF"><dcterms:extent>543 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-O596QE59/e452bc18-7981-4fdd-a055-463102de4978/TEXT"><dcterms:extent>30 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-O596QE59"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>1999</dcterms:issued><dc:creator>Borštnar, Simona</dc:creator><dc:creator>Čufer, Tanja</dc:creator><dc:creator>Rudolf, Zvonimir</dc:creator><dc:creator>Vrhovec, Ivan</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:33</dc:format><dc:format xml:lang="sl">str. 43-53</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:9752281</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-O596QE59</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Croatian Medical Association - Croatian Society of Radiology</dc:publisher><dc:publisher xml:lang="sl">Slovenian Medical Society - Section of Radiology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="sl">Breast neoplasms</dc:subject><dc:subject xml:lang="sl">dojke</dc:subject><dc:subject xml:lang="sl">Plasminogen activator inhibitor 1</dc:subject><dc:subject xml:lang="sl">Plasminogen activator inhibitor 2</dc:subject><dc:subject xml:lang="sl">Prognosis</dc:subject><dc:subject xml:lang="sl">prognoza</dc:subject><dc:subject xml:lang="sl">rak (medicina)</dc:subject><dc:subject xml:lang="sl">Recurrence</dc:subject><dc:subject xml:lang="sl">Urokinase</dc:subject><dc:subject xml:lang="sl">urokinaze</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancer| Napovedni pomen urokinaznega aktivatorja plazminogena in njegovih inhibitorjev pri bolnicah z rakom dojk|</dc:title><dc:description xml:lang="sl">Urokinase plasminogen activator (uPA) and its inhibitors, PAI-1 and PAI-2, play an important role in iritercellular tissue degradation, thus promoting tumor cell invasion into the adjoining structures and metastasizing. Our studywas aimed to assess a possible prognostic value of uPA, PAI-1 and PAI-2 in a retrospective series of 87 patients with breast cancer stage I-III, whosecytosols were stored in the archives of the, Institute of Oncology in Ljubljana. The median follow-up was 35 months. The prognostic value of the established prognostic factors and uPA, PAI-1 and PAI-2 were evaluated by means of univariate statistical analysis and partial multivariate models. The obtained uPA values were very low and did not correlate with the disease free survival, whereas PAI-1 and PAI-2 significantly influenced the time to the first recurrence. Patients with PAI-1 values above 5 ng/mg proteins had statistically significantly worse disease free survival than the patients withlower PAI-1 values (58% vs. 85%). In the case of PAI-2, the situation wasjust the opposite: the patients with PAI-2 values exceeding 6.4 ng/mg proteins had statistically significantly better 3-year disease free survival than the patients with lower values (90% vs. 60%). Both, PAI-1 and PAl-2 retained their independent prognostic value, irrespective of the addition of the established prognostic factors to partial multivariate models, and only with locally advanced disease the prognostic value of PAI-1 was greater than that of PAI-2</dc:description><dc:description xml:lang="sl">Urokinazni aktivator plazminogena (u-PA), in njegova inhibitorja (PAI- 1 in PAI-2) igrajo pomembno vlogo pri razgradnji medceličnega tkiva in s tem pri prodoru tumorskih celic v okolico ter metastaziranju. Namen naše raziskave je bil ugotoviti morebitno napovedno vrednost uPA, PAI-1 in PAI-2 v retrospektivni seriji 87 bolnic z rakom dojke stadijev I-III, njihove citosolehranimo na Onkološkem inštitutu v Ljubljani. Srednja opazovalna doba je bila 35 mesecev. Napovedni pomen uveljavljenih napovednih dejavnikov ter uPA, PAI-1 in PAI-2 smo ocenjevali z univariatno statistično analizo in delnimi multivariatnimi modeli. Vrednost uPA so bile zelo nizke in niso korelirale s preživetjem brez znamenj bolezni, PAI-1 in PAI-2 pa sta značilno vplivala na čas prve ponovitve bolezni. Bolnice, ki so imele vrednost PAI-1 večjo od 5ng/mg pro- teinov, so imele statistično značilno slabše preživetje brez znamenj bolezni kot bolnice z manjšimi vrednostmi (58% vs 85% , p = 0.0046). PAI-2 je pokazal nasprotno sliko, bolnice z vred- nostmi PAI-2 večjimi od 6.4 ng/mg proteinov so imele statistično značilno boljše triletno preživetje brez znamenj bolezni kot bolnice z manjšimi vrednostmi ( 90% vs 48%, Ir= 0.0178). PAI-1 in PAI-2 sta ohranila svojo neodvisno napovedno vrednost ob dodajanju uveljavljenih napovednih dejavnikov v delne multivariatne modele in le lokalna razširjenost bolezni je pokazala večjo napovedno moč od PAI-1 in PAI-2</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-O596QE59"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-O596QE59" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-O596QE59/d8ae40f1-4052-465b-a0fa-64a110f7ad70/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Onkološki inštitut Ljubljana</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-O596QE59/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-O596QE59" /></ore:Aggregation></rdf:RDF>